Albireo Pharma, Inc. (NASDAQ:ALBO – Get Rating) insider Martha J. Carter sold 938 shares of the business’s stock in a transaction dated Thursday, January 19th. The stock was sold at an average price of $43.90, for a total transaction of $41,178.20. Following the transaction, the insider now owns 14,626 shares in the company, valued at $642,081.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Albireo Pharma Stock Performance
Shares of ALBO stock opened at $43.81 on Monday. The firm’s 50 day moving average price is $25.87 and its 200-day moving average price is $22.52. Albireo Pharma, Inc. has a one year low of $16.02 and a one year high of $44.40. The firm has a market cap of $906.91 million, a P/E ratio of -6.52 and a beta of 0.81.
Albireo Pharma (NASDAQ:ALBO – Get Rating) last issued its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($1.89) EPS for the quarter, missing the consensus estimate of ($1.86) by ($0.03). Albireo Pharma had a negative return on equity of 97.13% and a negative net margin of 228.51%. The company had revenue of $9.83 million during the quarter, compared to analyst estimates of $9.68 million. As a group, research analysts predict that Albireo Pharma, Inc. will post -7.86 EPS for the current fiscal year.
Hedge Funds Weigh In On Albireo Pharma
Analysts Set New Price Targets
A number of equities analysts recently weighed in on ALBO shares. Cowen lowered shares of Albireo Pharma from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $68.00 to $48.00 in a research report on Wednesday, January 11th. StockNews.com started coverage on shares of Albireo Pharma in a report on Wednesday, October 12th. They issued a “sell” rating on the stock. Guggenheim lowered shares of Albireo Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, January 11th. Robert W. Baird boosted their target price on shares of Albireo Pharma from $43.00 to $55.00 and gave the company an “outperform” rating in a report on Wednesday, October 12th. Finally, Jefferies Financial Group lowered shares of Albireo Pharma from a “buy” rating to a “hold” rating and decreased their target price for the company from $49.00 to $42.00 in a report on Wednesday, January 11th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $48.00.
About Albireo Pharma
Albireo Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases.
- Get a free copy of the StockNews.com research report on Albireo Pharma (ALBO)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.